AstraZeneca Historical Balance Sheet
AZN Stock | 10,468 100.00 0.95% |
Trend analysis of AstraZeneca PLC balance sheet accounts such as Short Long Term Debt Total of 30.1 B, Other Current Liabilities of 20.8 B or Total Current Liabilities of 32.1 B provides information on AstraZeneca PLC's total assets, liabilities, and equity, which is the actual value of AstraZeneca PLC to its prevalent stockholders. By breaking down trends over time using AstraZeneca PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC is a good buy for the upcoming year.
AstraZeneca PLC Inventory |
|
AstraZeneca |
About AstraZeneca Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of AstraZeneca PLC at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.
AstraZeneca PLC Balance Sheet Chart
Add Fundamental
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of AstraZeneca PLC balance sheet. This account contains AstraZeneca PLC investments that will expire within one year. These investments include stocks and bonds that can be liquidated by AstraZeneca PLC fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most accounts from AstraZeneca PLC's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, AstraZeneca PLC's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 20.8 B, whereas Accounts Payable is forecasted to decline to about 2.8 B.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 30.8B | 29.2B | 28.6B | 30.1B | Total Assets | 105.4B | 96.5B | 101.1B | 106.2B |
AstraZeneca PLC balance sheet Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.4B | 66.7B | 105.4B | 96.5B | 101.1B | 106.2B | |
Short Long Term Debt Total | 18.2B | 20.4B | 30.8B | 29.2B | 28.6B | 30.1B | |
Other Current Liab | 12.9B | 14.4B | 16.0B | 16.3B | 19.8B | 20.8B | |
Total Current Liabilities | 18.1B | 20.3B | 22.6B | 26.3B | 30.5B | 32.1B | |
Total Stockholder Equity | 13.1B | 15.6B | 39.3B | 37.0B | 39.1B | 41.1B | |
Property Plant And Equipment Net | 8.3B | 8.9B | 10.2B | 9.4B | 10.5B | 6.8B | |
Net Debt | 12.9B | 12.5B | 24.5B | 23.1B | 22.8B | 23.9B | |
Retained Earnings | 2.8B | 5.3B | 1.7B | (574M) | 4.5B | 8.5B | |
Accounts Payable | 1.8B | 2.4B | 2.8B | 2.6B | 3.3B | 2.8B | |
Cash | 5.4B | 7.8B | 6.3B | 6.2B | 5.8B | 4.7B | |
Non Current Assets Total | 45.8B | 47.2B | 79.1B | 73.9B | 76.1B | 79.9B | |
Non Currrent Assets Other | 1.7B | 1.1B | 1.1B | 1.1B | 5.6B | 5.9B | |
Cash And Short Term Investments | 6.2B | 8.0B | 6.4B | 6.4B | 5.9B | 5.8B | |
Net Receivables | 3.6B | 3.8B | 6.0B | 7.2B | 8.4B | 8.8B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.4B | 1.6B | 1.6B | 1.4B | |
Liabilities And Stockholders Equity | 61.4B | 66.7B | 105.4B | 96.5B | 101.1B | 106.2B | |
Non Current Liabilities Total | 28.7B | 30.8B | 43.5B | 33.1B | 31.4B | 33.0B | |
Inventory | 3.2B | 4.0B | 9.0B | 4.7B | 5.4B | 5.7B | |
Other Current Assets | 2.6B | 3.7B | 4.8B | 4.4B | 5.4B | 5.2B | |
Total Liab | 46.8B | 51.1B | 66.1B | 59.4B | 62.0B | 65.1B | |
Property Plant And Equipment Gross | 8.3B | 8.9B | 10.2B | 9.4B | 19.1B | 20.1B | |
Total Current Assets | 15.6B | 19.5B | 26.2B | 22.6B | 25.1B | 15.3B | |
Short Term Debt | 2.0B | 2.4B | 2.9B | 6.5B | 5.4B | 5.7B | |
Other Assets | 3.5B | 4.3B | 5.3B | 4.2B | 4.8B | 5.0B | |
Other Stockholder Equity | 7.8B | 8.0B | 35.1B | 33.5B | 33.3B | 35.0B | |
Accumulated Other Comprehensive Income | (143M) | 881M | 111M | (1.6B) | (949M) | (996.5M) | |
Intangible Assets | 20.8B | 20.9B | 42.4B | 39.3B | 38.1B | 40.0B | |
Other Liab | 10.3B | 10.5B | 13.0B | 8.5B | 9.8B | 6.7B | |
Long Term Debt | 15.7B | 17.5B | 28.1B | 23.0B | 22.4B | 11.3B | |
Good Will | 11.7B | 11.8B | 20.0B | 19.8B | 20.0B | 21.1B | |
Property Plant Equipment | 8.3B | 8.9B | 10.2B | 9.4B | 10.9B | 7.9B | |
Net Tangible Assets | (19.4B) | (17.2B) | (23.1B) | (22.1B) | (19.9B) | (20.9B) | |
Short Long Term Debt | 1.8B | 2.2B | 1.7B | 5.3B | 5.1B | 5.4B | |
Capital Surpluse | 4.4B | 4.4B | 7.9B | 8.0B | 9.2B | 6.4B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AstraZeneca Stock
Balance Sheet is a snapshot of the financial position of AstraZeneca PLC at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.